Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and machined parts. Further, it provides engineering consulting and placement services, as well as quality and regulatory consulting services. The company offers its products under the Pro-Dex brand name. Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, dental offices, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PDEX
CUSIPN/A
Phone949-769-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio7.63
Quick Ratio5.90
Price-To-Earnings
Trailing P/E Ratio12.98
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.94 million
Price / Sales1.34
Cash Flow$1.3663 per share
Price / Cash4.93
Book Value$3.42 per share
Price / Book1.97
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$5.08 million
Net Margins9.94%
Return on Equity13.54%
Return on Assets11.93%
Miscellaneous
Employees76
Outstanding Shares4,350,000
Market Cap$29.39
Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions
What is Pro-Dex's stock symbol?
Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."
How were Pro-Dex's earnings last quarter?
Pro-Dex Inc (NASDAQ:PDEX) released its earnings results on Tuesday, February, 10th. The medical instruments supplier reported ($0.05) EPS for the quarter. The medical instruments supplier earned $2.80 million during the quarter, compared to the consensus estimate of $2.60 million. Pro-Dex had a return on equity of 13.54% and a net margin of 9.94%. View Pro-Dex's Earnings History.
What price target have analysts set for PDEX?
1 analysts have issued 12 month target prices for Pro-Dex's shares. Their predictions range from $9.00 to $9.00. On average, they expect Pro-Dex's share price to reach $9.00 in the next year. This suggests a possible upside of 33.6% from the stock's current price. View Analyst Ratings for Pro-Dex.
What is the consensus analysts' recommendation for Pro-Dex?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pro-Dex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Pro-Dex's key competitors?
Some companies that are related to Pro-Dex include Sensus Healthcare (SRTS), Invuity (IVTY), Restoration Robotics (HAIR), Alphatec (ATEC), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Neovasc (NVCN), Spectral Medical (EDTXF), SANUWAVE Health, Inc. Common Stock (SNWV), CAS Medical Systems (CASM), iCAD (ICAD), Repro-Med Systems (REPR), Nephros (NEPH), CELLECT BIOTECH/S (APOP) and Valeritas (VLRX).
Who are Pro-Dex's key executives?
Pro-Dex's management team includes the folowing people:
- Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 57)
- Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 48)
- Mr. Phillip S. Brown, VP & GM of OMS
- Angel Rebamontan Domingo, Director of Regulatory Affairs & Quality Assurance
Has Pro-Dex been receiving favorable news coverage?
Press coverage about PDEX stock has been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pro-Dex earned a news impact score of 0.04 on Accern's scale. They also gave press coverage about the medical instruments supplier an impact score of 46.93 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Pro-Dex?
Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pro-Dex's stock price today?
One share of PDEX stock can currently be purchased for approximately $6.7359.
How big of a company is Pro-Dex?
Pro-Dex has a market capitalization of $29.39 million and generates $21.94 million in revenue each year. Pro-Dex employs 76 workers across the globe.
How can I contact Pro-Dex?
Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected]
MarketBeat Community Rating for Pro-Dex (NASDAQ PDEX)
MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote "Outperform" if you believe PDEX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days.
